

Biological activity of two botulinum toxin type A complexes (Dysport[®] and Botox[®]) in volunteers

A double-blind, randomized, dose-ranging study

Kai Wohlfarth · Imke Schwandt · Florian Wegner ·
Tim Jürgens · Götz Gelbrich · Armin Wagner ·
Ulrich Bogdahn · Wilhelm Schulte-Mattler

Published online: 2 July 2009
© Springer-Verlag 2009

Erratum to: J Neurol (2008) 255:1932–1939
DOI 10.1007/s00415-008-0031-7

Figure 4 has been published incorrectly. The correct figure is reproduced here.




Fig. 4 Likelihood ratios for various dose equivalence factors (DEQFs) relative to the belief that DEQF = 2 (2 units of Dysport[®]:1 unit of Botox[®])

The online version of the original article can be found under doi:[10.1007/s00415-008-0031-7](https://doi.org/10.1007/s00415-008-0031-7).

K. Wohlfarth (✉)
Klinik für Neurologie, HELIOS Klinikum,
Pieskower Str. 33, 15526 Bad Saarow, Germany
e-mail: kai.wohlfarth@helios-kliniken.de

K. Wohlfarth · I. Schwandt · F. Wegner · A. Wagner
Dept. of Neurology, University of Leipzig,
Liebigstr. 22a, 04103 Leipzig, Germany

T. Jürgens · U. Bogdahn · W. Schulte-Mattler
Dept. of Neurology, University of Regensburg,
Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany

G. Gelbrich
Coordination Center for Clinical Trials Leipzig (KKSL),
Haertelstr. 16–18, 04103 Leipzig, Germany